Reference : A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden
Scientific journals : Article
Human health sciences : Oncology
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/2268/24064
A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden
English
Le Gall, C. [> > > >]
Bellahcene, Akeila mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases >]
Bonnelye, E. [> > > >]
Gasser, J. A. [> > > >]
Castronovo, Vincenzo mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire >]
Green, J. [> > > >]
Zimmermann, J. [> > > >]
Clezardin, P. [> > > >]
15-Oct-2007
Cancer Research
Amer Assoc Cancer Research
67
20
9894-9902
Yes (verified by ORBi)
International
0008-5472
Philadelphia
[en] Cathepsin K ; Breast cancer ; Bone metastases
[en] Osteoclasts mediate bone destruction in breast cancer skeletal metastases. Cathepsin K is a proteinase that is secreted by osteoclasts and degrades bone. Here, immohistochemistry revealed that cathepsin K was expressed not only by osteoclasts but also by breast cancer cells that metastasize to bone. Following intratibial injection with cathepsin K-expressing human BT474 breast cancer cells, tumor-bearing mice treated with a clinical dosing regimen of cathepsin K inhibitor (CKI; 50 mg/kg, twice daily) had osteolytic lesions that were 79% smaller than those of tumor-bearing mice treated with the vehicle. The effect of CKI was also studied in a mouse model in which the i.v. inoculation of human B02 breast cancer cells expressing cathepsin K leads to bone metastasis formation. Drug administration was started before (preventive protocol) or after (treatment protocol) the occurrence of osteolytic lesions. In treatment protocols, CKI (50 mg/kg, twice daily) or a single clinical dose of 100 mu g/kg zoledronic acid (osteoclast inhibitor) reduced the progression of osteolytic lesions by 59% to 66%. CKI therapy also reduced skeletal tumor burden by 62% compared with vehicle, whereas zoledronic acid did not decrease the tumor burden. The efficacy of CKI at inhibiting skeletal tumor burden was similar in the treatment and preventive protocols. By contrast, CKI did not block the growth of s.c. B02 tumor xenografts in animals. Thus, CKI may render the bone a less favorable microenvironment for tumor growth by inhibiting bone resorption. These findings raise the possibility that cathepsin K could be a therapeutic target for the treatment of bone metastases.
Centre de Recherche en Cancérologie Expérimentale (CRCE)
Institut National de la Santé et de la Recherche Médicale ; Novartis Pharma ; League against Cancer (Rhône Committe) ; ARC Grants 3502 and 7853 ; European Commission (METABRE) ; Tournesol Program ; Association pour la Recherche sur les Tumeurs de la Prostate ; Association pour la Recherche sur le Cancer ; Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS
http://hdl.handle.net/2268/24064

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
LE GALL C CANCER RES 2007.pdfPublisher postprint665.23 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.